A Multicenter Randomized Phase III Study for Recurrent Glioblastoma Comparing Bevacizumab Alone With Dose-dense Temozolomide Followed by Bevacizumab (JCOG1308C, RE-GEND-pIII)
Phase of Trial: Phase III
Latest Information Update: 24 Aug 2017
At a glance
- Drugs Temozolomide (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms RE-GEND
- 11 Jul 2016 Planned primary completion date changed from 1 May 2022 to 1 Jul 2022.
- 11 Jul 2016 Status changed from not yet recruiting to recruiting.
- 06 May 2016 New trial record